技术与方法 |
|
|
|
|
一株针对人EGFR的单链抗体克隆与哺乳细胞表达 * |
高鑫1,韦攀健2,闫卓红2,易玲2,王小珏1,杨斌2,张洪涛1,***() |
1 北京市结核病胸部肿瘤研究所中心实验室 北京 101149 2 首都医科大学附属北京胸科医院肿瘤免疫室 北京 101149 |
|
Cloning and Expression of Single Chain Antibody Against Human EGFR |
Xin GAO1,Pan-jian WEI2,Zhuo-hong YAN2,Ling YI2,Xiao-jue WANG1,Bin YANG2,Hong-tao ZHANG1,***() |
1 Central Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China 2 Department of Tumor Immunology, Beijing Chest Hospital, Capital Medical University,Beijing 101149, China |
引用本文:
高鑫,韦攀健,闫卓红,易玲,王小珏,杨斌,张洪涛. 一株针对人EGFR的单链抗体克隆与哺乳细胞表达 *[J]. 中国生物工程杂志, 2018, 38(5): 73-78.
Xin GAO,Pan-jian WEI,Zhuo-hong YAN,Ling YI,Xiao-jue WANG,Bin YANG,Hong-tao ZHANG. Cloning and Expression of Single Chain Antibody Against Human EGFR. China Biotechnology, 2018, 38(5): 73-78.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180510
或
https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I5/73
|
[1] |
Salomon D S, Brandt R, Ciardiello F , et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 1995,19(3):183-232.
doi: 10.1016/1040-8428(94)00144-I
pmid: 7612182
|
[2] |
Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 2006,7(7):505-516.
doi: 10.1038/nrm1962
pmid: 16829981
|
[3] |
Hynes N E, Lane H A . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005,5(5):341-354.
doi: 10.1038/nrc1609
pmid: 15864276
|
[4] |
Hubbard J M, Alberts S R . Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res, 2013,6(2):47-55.
pmid: 23745159
|
[5] |
Cho S H, Park L C, Ji J H , et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer Chemother Pharmacol, 2012,70(2):315-320.
doi: 10.1007/s00280-012-1876-0
pmid: 3222222760226
|
[6] |
Fang W, Zhang J, Liang W , et al. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis, 2013,5(5):585-592.
doi: 10.3978/j.issn.2072-1439.2013.09.15
pmid: 24255770
|
[7] |
Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med, 2008,358(11):1160-1174.
doi: 10.1016/S8756-3452(08)79180-1
|
[8] |
Couzin-Frankel J . Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013,342(6165):1432-1433.
doi: 10.1126/science.342.6165.1432
|
[9] |
Libermann T A, Nusbaum H R, Razon N , et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 1985,313(5998):144-147.
doi: 10.1038/313144a0
|
[10] |
Yokota T, Milenic D E, Whitlow M , et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res, 1992,52(12):3402-3408.
|
[11] |
Liu X, Jiang S, Fang C , et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res, 2015,75(17):3596-3607.
doi: 10.1158/0008-5472.CAN-15-0159
pmid: 26330166
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|